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Bisphosphonates are the most widely prescribed medicines for the treatment of osteoporosis and have generally been regarded as
well-tolerated and safe drugs. Since 2005, there have been numerous case reports about atypical fractures of the femur linked to
long-term treatment of osteoporosis with bisphosphonates. Some attempts to characterize pathophysiology and epidemiology of
these fractures havebeen published aswell. However, asthe American Society forBoneandMineralResearch (ASBMR)concluded
in their task force report, the subject warrants further studies.
1.Introduction
Bisphosphonatesare widely used fortreatment ofosteoporo-
sis. It has been shown in the randomized clinical studies
that bisphosphonates reduce the incidence of osteoporotic
vertebral and hip fractures when used for the treatment of
postmenopausal osteoporosis [1–4]. Bisphosphonates act by
inhibiting the osteoclast function and inducing osteoclast
apoptosis. This leads to suppression of bone resorption
and increase of bone mineral density. Based on studies on
experimental animals, it has been shown, however, that
suppression of bone resorption might lead to suppression of
bone turnover and creation of hard, but more brittle bone
[5, 6].
The optimal duration of the bisphosphonate therapy
remains also a question. Based on current evidence, the
continuingofbisphosphonatetherapybeyondﬁveyearsdoes
not seem to lower osteoporotic fracture risk as much as the
ﬁrst years of therapy [7].
In 2005, Odvina et al. published a case series about nine
osteoporotic patients on long-term bisphosphonate therapy
who had acquired atypical fractures [8]. In their report,
suppressed bone turnoverby bisphosphonates was suggested
as etiologic factor for the fractures.
Since the publishing of this report, a few case reports
aboutthesubjecthavebeenpublished.TheAmericanSociety
for Bone and Mineral Research also has published recently
a task force report about atypical femoral fractures [9]a s
well as two international osteoporosis societies [10]. Some
review articles about the subject have also been published
recently [11, 12]. In this paper, published case series and
reports are reviewed as well as current knowledge about the
epidemiology and pathophysiology of these fractures.
2.Published Case Reportsand CaseSeries
The original case series of Odvina et al. [8] consisted of
nine patients having fractures in various nonvertebral sites,
actually only three patients had fractures of femoral shaft,
while two other patients had fractures of proximal femur.
The patients in this original case series were well studied; the
case series included histomorphometric data, biomechanical
markers of bone turnover and bone densitometric measure-
ments. They noted that in the histomorphometric samples
a severely suppressed bone turnover was seen. It also was
suggested that use of estrogens or corticosteroids could be
predisposing factors for these fractures, since three of the
patients were on estrogen therapy and two of them had used
corticosteroids.
After the original report by Odvina et al., a number
of case reports have been published [13–29]. In the case
series by Kwek et al. [18] the major radiologic features of
these fractures were deﬁned as (a) cortical thickening in2 Journal of Osteoporosis
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Figure 1: A case of bilateral femur fractures in a patient who had
been on alendronate therapy for six years.
the lateral (tension) side of the subtrochanteric region, (b)
transverse fracture, and (c) medial cortical spike (Figure 1).
These features were included also in the ASBMR deﬁnition
of atypical femoral fractures. In the ASBMRtask force report
the atypical fractures were, however, also required to be
associated with no trauma or minimal trauma and to be
noncomminuted.
The original case series by Odvina et al. included two
patients with bilateral fractures of femoral shaft. Subsequent
case reports and case series have included both unilateral
[13–16, 18, 20, 25]a n db i l a t e r a lc a s e s[ 16, 17, 25–29]. It
has been demonstrated that patients having unilateral atyp-
ical femoral fractures often have stress injury-like cortical
hypertrophy in their contralateral limb [14], suggesting that
bisphosphonate eﬀect on these patients’ femurs most likely
is bilateral. In the series by Kwek et al. [18], the incidence of
contralateral cortical hypertrophy was estimated to be 53%.
Another characteristic feature of atypical femoral frac-
tures are prodromal symptoms. Goh et al. [14]w e r et h e
ﬁrst authors reporting of ipsilateral prodromal pain before
subsequent fracture. In their series of nine alendronate-
treated patients with atypical subtrochanteric fractures,
ﬁve patients had experienced pain or discomfort in the
fractured limb, between two to six months before the injury.
The prodromal symptoms and cortical hypertrophy were
correlated with radiologic cortical stress reaction by Koh
et al. in their retrospective series of 16 patients [30]. They
identiﬁed a “dreaded black line”, a radiologic ﬁnding known
to be associated with nonunion of stress fractures [31], in
four patients’ X-rays taken because of prodromal symptoms
before the fracture. They suggested that the presence of the
dreaded black line in a symptomatic patient should indicate
prophylactic nailing, since in their retrospective series it
seemed to herald a complete fracture.
The case reports and case series published so far have
mostly includedpatients on alendronate therapy [13–20, 25–
29]. There are, however, reports about patients with atypical
fractures who have been on pamidronate [21]o rr i s e d r o n a t e
[22–25] as well. The greater amount of cases linked to al-
endronate than other bisphosphonates is most probably a
consequence of alendronate’s position as the most frequently
used bisphosphonate for (postmenopausal) osteoporosis.
In the published case series and reports it has been
pointed out that concomitant use of other pharmacologic
agents with alendronate could be a predisposing factor
for atypical femoral fractures. In the original Odvina’s
report [8], coadministration of estrogen and glucocorticoids
were raised as potential predisposing factors. In subsequent
reports frequent use of these agents has also been noted
as well as use of oral proton-pump inhibitors [16, 21,
27, 28]. Giusti et al. in their systematic review estimated
the concomitant use of oral glucocorticoids to be 25.5%,
estrogens 11.8%, and proton pump inhibitors 38.9% in
patients with atypical fractures. There is a good number
of published cases of patients not using any of the above-
mentioned agents [14, 18], however, and therefore a direct
causal relationship cannot be established. Moreover, the use
of the above-mentioned agents may well be frequent in
osteoporotic patients. Glucocorticoid use is a well-known
cause of secondary osteoporosis, estrogens are often used
by postmenopausal women, and bisphosphonates cause
dyspeptic symptoms that may lead to use of proton pump
inhibitors.
3.Pathophysiology
In the original case series by Odvina et al. [8], an iliac crest
bone biopsy was obtained from all nine patients. All of their
patients showed a severe depression of bone formation with
absence of double-tetracycline labelling. The case reports
and case series reviewed in this paper include data of iliac
crest bone biopsies after double-tetracycline labeling from
19 patients [8, 16, 20, 22, 26, 29]. Of them, 18 have shown
severe depression of bone turnover(deﬁned as complete lack
of tetracycline labels).
It is known that long-term bisphosphonate use sup-
presses bone turnover, but in the previous histomorphome-
tric studies single or double tetracycline labels have almost
always been detected, contrary to ﬁndings in patients with
atypical fractures [32, 33]. Also, Bone et al. found that
even combination therapy of alendronate and estrogen did
not result in complete disappearance of tetracycline labels
[34]. The samples in these studies were, however, collected
from patients treated for 2-3 years with bisphosphonates.
There are some studies [35, 36] where the authors have
collected histomorphometric samples from patients treated
with alendronate for 5-6 years in average. In both of these
studies, the bone turnover rate was clearly lowered and
in the study of Chapurlat et al. double-tetracycline labels
were lacking in 1/3 of patients [36]. In light of these
ﬁndings, it seems prudent to state that long-term (over
ﬁve years) therapy with bisphosphonates may lead to a
severe suppression of bone turnover that in itself may be a
predisposing factor for the atypical fractures of femur.
The safety of long-term bisphosphonate therapy has
been questioned earlier on the basis of experimental studies.Journal of Osteoporosis 3
Mashiba et al. [5] treated beagle dogs with alendronate
or risedronate for one year and observed a suppression of
boneturnoverandincreaseofmicrodamageaccumulationin
dogs’ribs.Thedosesusedwereﬁvetimesgreaterthanclinical
doses used in humans for treatment of osteoporosis. Same
phenomenonwas observedin beagles’vertebrae and femoral
necks [6]. There was no diﬀerence between alendronate and
risedronate in the microdamage accumulation suggesting
that possible adverse eﬀects of bisphosphonates on bone
should not be restricted to alendronate only.
Bone turnover in patients with atypical fractures has
also been estimated with the help of biochemical markers
(urinary excretion of N-telopeptide and/or hydroxyproline)
insomeofthecasereportsandseriesmentionedabove[8,16,
20, 25–27]. The results from these studies are inconclusive.
There are reports where the markers of bone turnover have
indicated decreased turnover [16] and increased turnover
[26]. However, in most reports, the biochemical markers
have been within the reference limits [8, 20, 25, 27]. This
mostprobablyreﬂectsthefactthatbiochemicalmarkershave
poor sensitivity and speciﬁcity for detection of low bone
turnover. Similarly, the bone mineral density data of the
published cases does not provide any conclusive evidence of
the pathophysiology of the atypical fractures of femur.
4.Epidemiology
There is little epidemiologic data concerning the atypical
fractures of femur in bisphosphonate users so far. There have
been some attempts to determine the incidence of these frac-
tures and to ﬁnd out whether long-term bisphosphonate use
might lead to rising incidence of subtrochanteric/diaphyseal
femoral fractures.
Schilcher and Aspenberg identiﬁed the incidence of
atypical fractures in the area of two healthcare districts in
Sweden[37].With the help ofnational drug deliveryregister,
they were able to ﬁnd out the prevalence of bisphosphonate
use in their area. They were able to ﬁnd out 8 cases where
fracture conﬁguration was consistent with the radiologic
appearance of atypical fractures. Of these patients, ﬁve were
bisphosphonate users. Using these ﬁndings they estimated
the incidence of atypical fractures in patients on continuous
bisphosphonate therapy to be 1/1000 per year (CI: 0.3–2).
Black et al. performed secondary analyses of three large
randomized, controlled bisphosphonate trials [38]. Among
14,195 women they were able to ﬁnd 12 fractures in 10
patients. The fractures were classiﬁed as occurring in the
subtrochanteric ordiaphyseal femur.Aweakness ofthestudy
wasthelackofradiographsofallthepatients.Theyestimated
the rate of subtrochanteric or diaphyseal fractures of femur
to be 2.3 per 10,000 patient-years. The relative hazard rates
for alendronate (FIT trial) was 1.03; for zoledronic acid
(HORIZON-PFT trial) 1.50 and for continued alendronate
use (FLEX trial) 1.33. The conﬁdence intervals were wide,
probably due to the fact that none of these trials was
originally powered to detect a relatively uncommon side-
eﬀect of the bisphosphonates.
Another method to estimate the occurrence of subtro-
chanteric or diaphyseal femur fractures in bisphosphonate-
treated patients was utilized by Abrahamsen et al. [39].
Their study included a cross-sectional and matched control
cohort studies. In the cross-sectional part they were able to
ﬁnd out that the same percentage (7%) of subtrochanteric
fracture patients were alendronate users as of the patients
with hip fractures. In the cohort study they found out that
alendronate use carried a similar risk for subtrochanteric
or diaphyseal femur fractures (HR = 1.64) than for hip
fractures (HR = 1.50). Conclusion of the investigators was
that the risk for the proximal femoral fractures was caused
by the osteoporosis itself, since the risk was similar for both
these fractures. The limitations of the study include the lack
of analysis of the radiographs. The fracture groups included
also high-energy patients.
Vestergaard et al. studied the incidence of sub-
trochanteric and diaphyseal femoral fractures both before
and after the start of various drugs against osteoporosis
[40]. Their study was based on hospital discharge registers
and included age- and gender-matched controls. They were
not able to ﬁnd an increased incidence of the above-
mentioned fractures among 103,562 patients receiving drugs
against osteoporosis. Although the atypical fractures were
not speciﬁcally identiﬁed since no X-rays were analyzed,
the study supports the conclusion that the skeletal beneﬁts
of antiresorptive agents outweigh the possible skeletal side-
eﬀects of bisphosphonates.
We have also made an estimate of the incidence of
atypical fractures of femur in our university hospital’s
catchment area using methods similar to Schilcher and
Aspenberg (unpublished data). Interestingly, we resulted in
an estimate of incidence of 0.5/1,000 patient-years among
bisphosphonate-users, not very far from the estimate by
Schilcher and Aspenberg.
5.Conclusions
Based on published case reports and case series, the atypical
fractures of femur seem to occur rarely without a long-term
treatment of osteoporosis with bisphosphonates. Since the
evidence-base for osteoporosis treatment with bisphospho-
nates for more than ﬁve years is relatively thin, it seems
prudent to consider the beneﬁts and risks on a patient
who has received the treatment for more than ﬁve years.
However, as it is not yet known whether the risk of adverse
eﬀects of medication can be avoided by drug holidays or
by discontinuing the bisphosphonate therapy, more research
is clearly needed. The atypical femoral fractures with their
possible prodromal symptoms should be remembered on
any patient on bisphosphonate therapy, especially if they
are receiving therapy with estrogens, oral glucocorticoids, or
proton pump inhibitors.
Based on the available data, the most likely pathophysi-
ologic mechanism leading to these fractures seems to be the
suppression of bone turnover by bisphosphonates. However,
more research in this regard is needed as well.4 Journal of Osteoporosis
Finally, the true incidence and epidemiology of this
possible adverse eﬀect of osteoporosis treatment is very
poorly known. Therefore, it is very easy to agree with
ASBMR,callingforinternational registry for casesofatypical
femoral fractures. The guidelines suggested for the future
research can be agreed as well in order to be better able to
characterize these fractures.
While there is concern that there may be more atypical
femoral fractures in future, when more osteoporotic patients
have received bisphosphonate therapy for more than ﬁve
years, there is not yet any evidence which would urge
physicians to discontinue the therapy, at least before ﬁve
years. In the light of current knowledge, the positive eﬀects
of bisphosphonates outweigh their adverse eﬀects.
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